Rebuttal from Authors re: Edward M. Messing. Node Positive Renal Cell Cancer. Who Can Be Helped? Eur Urol 2007;51:1477-8

European Urology

Volumn 51, Issue 6, 2007, Pages 1478-1480

  Karakiewicz, Pierre ^a   Perrotte, Paul ^a   Trinh, Quoc Dien ^a   Patard, Jean Jacques ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

AUTHOR; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; EDITORIAL; HUMAN; KIDNEY CARCINOMA; LYMPHADENECTOMY; METASTASIS; NEPHRECTOMY; NOMOGRAM; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; NEPHRECTOMY; PATIENT SELECTION; PROGNOSIS; REFERRAL AND CONSULTATION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34247358308     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.067     Document Type: Editorial

References (10)

1. Messing E.M. Node positive renal cell cancer. Who can be helped?. Eur Urol. 51 (2007) 1477-1478
2. Karakiewicz P.I., Trinh Q.-D., Bhojani N., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol. 51 (2007) 1616-1624
3. Canfield S.E., Kamat A.M., Sanchez-Ortiz R.F., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175 (2006) 864-869
4. Briganti A., Chun F.K., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1027
5. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 50 (2006) 1254-1261
6. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II, 2005:4511.
7. Patard J.J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
8. Blom J.H., van Poppel H., Marechal J.M., et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36 (1999) 570-575
9. DiMarco D.S., Zincke H., Sebo T.J., et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
10. Briganti A., Chun F.K., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98 (2006) 788-793